Postmenopausal Osteoporosis
📧 Sign up to get email alerts when something new happens for Postmenopausal Osteoporosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-09-29Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of LY06006 in Postmenopausal Women With Osteoporosis at High Risk for Fracture [Phase 3]
Phase 3 trial evaluating efficacy and safety of LY06006 in postmenopausal osteoporosis at high fracture risk.
-
EMA approval · 2021-09-27EMA Authorised: Raloxifene Teva (raloxifene hydrochloride) — Teva B.V.
European Medicines Agency has authorised Raloxifene Teva (raloxifene hydrochloride) for osteoporosis in postmenopausal women.
-
FDA approval · 2021-09-07FDA Approved: TERIPARATIDE — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application for teriparatide submitted by Prasco Laboratories. This action relates to a supplemental approva…
-
CLINICAL_TRIALS research · 2021-06-23Clinical Trial Update: Pravastatin Reduces Acute Phase Response of Zoledronic Acid [Phase 4]
Phase 4 trial investigating whether pravastatin reduces the acute phase response associated with zoledronic acid in postmenopausal osteoporo…
-
CLINICAL_TRIALS trial_result · 2021-06-23Clinical Trial Update: Clinical Pharmacokinetics and Pharmacodynamics Study of Different Doses of Zoledronic Acid [Phase 4]
Phase 4 pharmacokinetics/pharmacodynamics study evaluating different doses of zoledronic acid in postmenopausal osteoporosis.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-04-29Clinical Trial Update: The Effects of Melatonin Treatment on Bone, Marrow, Sleep and Blood Pressure [Phase 4]
Phase 4 clinical trial update on melatonin treatment effects related to bone, marrow, sleep, and blood pressure in postmenopausal osteoporos…
-
CLINICAL_TRIALS trial_result · 2021-01-22Clinical Trial Update: Denosumab and Teriparatide Study (DATA-HD and DATA-EX) [Phase 4]
Phase 4 trial update for denosumab and teriparatide in postmenopausal osteoporosis; results posted after completion.
-
CLINICAL_TRIALS trial_result · 2020-12-11Clinical Trial Update: Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis [Phase 3]
Phase 3 extension study update for abaloparatide in postmenopausal osteoporosis, completed with results posted.
-
FDA approval · 2020-11-16FDA Approved: TERIPARATIDE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for teriparatide submitted by Prasco Laboratories, expanding or updating the drug's regulatory statu…
-
FDA approval · 2020-10-23FDA Approved: TYMLOS — Supplemental Application (Radius Health, Inc.)
FDA approved a supplemental application for TYMLOS (abaloparatide) from Radius Health, Inc. The approval updates the product labeling.
-
FDA approval · 2020-10-13FDA Approved: BINOSTO — Supplemental Application (Radius Health, Inc.)
The FDA approved a supplemental application for BINOSTO (alendronate sodium) from Radius Health, Inc., supporting a label expansion/updated …
-
FDA approval · 2020-08-18FDA Approved: RALOXIFENE HYDROCHLORIDE — Original Application (Modavar Pharmaceuticals LLC)
FDA approved Modavar Pharmaceuticals' original application for raloxifene hydrochloride, enabling a generic version of the drug.
-
FDA approval · 2020-08-06FDA Approved: RISEDRONATE SODIUM — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for Risendronate Sodium from Aurobindo Pharma Limited.
-
FDA approval · 2020-06-19FDA Approved: IBANDRONATE SODIUM — Supplemental Application (Dr. Reddy's Laboratories Limited)
The FDA approved a supplemental application for ibandronate sodium submitted by Dr. Reddy's Laboratories Limited.
-
FDA approval · 2020-06-08FDA Approved: BINOSTO — Supplemental Application (Radius Health, Inc.)
FDA approves a supplemental application for BINOSTO (alendronate sodium) submitted by Radius Health, Inc.
-
EMA withdrawal · 2020-05-19EMA Withdrawn: Osseor (strontium ranelate) — Les Laboratoires Servier
The EMA has withdrawn Osseor (strontium ranelate) from the market.
-
CLINICAL_TRIALS trial_result · 2020-05-18Clinical Trial Update: Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)
A post-approval safety study update for bazedoxifene in the EU has completed with results posted.
-
EMA withdrawal · 2020-05-15EMA Withdrawn: Protelos (strontium ranelate) — Les Laboratoires Servier
The EMA withdrew Protelos (strontium ranelate) from the market for osteoporosis, postmenopausal indications.
-
FDA approval · 2020-04-06FDA Approved: TERIPARATIDE — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application for teriparatide submitted by Prasco Laboratories under NDA 021318.
-
FDA approval · 2019-12-17FDA Approved: IBANDRONATE SODIUM — Supplemental Application (Apotex Corp.)
The FDA approved a supplemental application for Apotex Corp. to market a generic ibandronate sodium product.
-
CLINICAL_TRIALS trial_result · 2019-11-26Clinical Trial Update: Study Evaluating ASTRA TECH Implant System, OsseoSpeed™ Implants in the Upper Jaw in Women With Osteoporosis [NA]
Clinical trial evaluating ASTRA TECH and OsseoSpeed implants in the upper jaw for women with osteoporosis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2019-11-14Clinical Trial Update: A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018) [Phase 3]
Phase 3 study MK-0822-018 in postmenopausal osteoporosis was terminated; Merck Sharp & Dohme posted results in 2019.
-
CLINICAL_TRIALS trial_result · 2019-11-06Clinical Trial Update: Efficacy and Safety of QL1206 in the Treatment of Postmenopausal Osteoporosis With High Fracture Risk [Phase 3]
Phase 3 clinical trial update on QL1206 for postmenopausal osteoporosis with high fracture risk, assessing efficacy and safety.
-
FDA approval · 2019-10-03FDA Approved: TERIPARATIDE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for Teriparatide submitted by Prasco Laboratories.
-
FDA approval · 2019-08-23FDA Approved: RALOXIFENE HYDROCHLORIDE — Supplemental Application (ScieGen Pharmaceuticals Inc)
FDA approved a supplemental application for raloxifene hydrochloride submitted by ScieGen Pharmaceuticals Inc.